As­traZeneca halts two PhI­II hy­per­kalemia stud­ies in­tend­ed to spot­light Lokel­ma’s clin­i­cal val­ue

As­traZeneca an­nounced ear­ly Fri­day morn­ing that it is stop­ping work on two late-stage tri­als de­signed to gath­er val­ue-added ev­i­dence for Lokel­ma in hy­per­kalemia, a chron­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER